113 related articles for article (PubMed ID: 3363012)
1. Concentration and distribution of thioridazine and metabolites in schizophrenic post-mortem brain tissue.
Svendsen CN; Hrbek CC; Casendino M; Nichols RD; Bird ED
Psychiatry Res; 1988 Jan; 23(1):1-10. PubMed ID: 3363012
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
Carrillo JA; Ramos SI; Herraiz AG; Llerena A; Agundez JA; Berecz R; Duran M; Benítez J
J Clin Psychopharmacol; 1999 Dec; 19(6):494-9. PubMed ID: 10587283
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.
Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J
Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048
[TBL] [Abstract][Full Text] [Related]
4. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine.
Eap CB; Souche A; Koeb L; Baumann P
Ther Drug Monit; 1991 Jul; 13(4):356-62. PubMed ID: 1780970
[TBL] [Abstract][Full Text] [Related]
5. Comparative anticholinergic properties of thioridazine, mesoridazine and sulforidazine.
Niedzwiecki DM; Cubeddu LX; Mailman RB
J Pharmacol Exp Ther; 1989 Jul; 250(1):126-33. PubMed ID: 2746492
[TBL] [Abstract][Full Text] [Related]
6. Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum.
Niedzwiecki DM; Cubeddu LX; Mailman RB
J Pharmacol Exp Ther; 1989 Jul; 250(1):117-25. PubMed ID: 2746491
[TBL] [Abstract][Full Text] [Related]
7. Serum concentrations of thioridazine, its major metabolites and serum neuroleptic-like activities in schizophrenics with and without tardive dyskinesia.
Widerlöv E; Häggström JE; Kilts CD; Andersson U; Breese GR; Mailman RB
Acta Psychiatr Scand; 1982 Oct; 66(4):294-305. PubMed ID: 7148482
[TBL] [Abstract][Full Text] [Related]
8. Drug distribution between blood and brain as a determinant of antipsychotic drug effects.
Tsuneizumi T; Babb SM; Cohen BM
Biol Psychiatry; 1992 Nov; 32(9):817-24. PubMed ID: 1360262
[TBL] [Abstract][Full Text] [Related]
9. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study.
Chakraborty BS; Midha KK; McKay G; Hawes EM; Hubbard JW; Korchinski ED; Choc MG; Robinson WT
J Pharm Sci; 1989 Oct; 78(10):796-801. PubMed ID: 2600782
[TBL] [Abstract][Full Text] [Related]
10. Important metabolites to measure in pharmacodynamic studies of chlorpromazine.
Chetty M; Moodley SV; Miller R
Ther Drug Monit; 1994 Feb; 16(1):30-6. PubMed ID: 8160251
[TBL] [Abstract][Full Text] [Related]
11. Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma.
Eap CB; Koeb L; Powell K; Baumann P
J Chromatogr B Biomed Appl; 1995 Jul; 669(2):271-9. PubMed ID: 7581903
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine.
Daniel WA; Syrek M; Haduch A; Wójcikowski J
Pol J Pharmacol; 1998; 50(6):431-42. PubMed ID: 10385926
[TBL] [Abstract][Full Text] [Related]
13. Absorption and excretion of thioridazine and mesoridazine in man.
Charalampous KD; Johnson PC; Estevez V
Dis Nerv Syst; 1974 Nov; 35(11):494-6. PubMed ID: 17896456
[TBL] [Abstract][Full Text] [Related]
14. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors.
Niedzwiecki DM; Mailman RB; Cubeddu LX
J Pharmacol Exp Ther; 1984 Mar; 228(3):636-9. PubMed ID: 6707914
[TBL] [Abstract][Full Text] [Related]
15. S-oxidation of thioridazine to psychoactive metabolites: an oral dose-proportionality study in healthy volunteers.
Chakraborty BS; Hawes EM; McKay G; Hubbard JW; Korchinski ED; Midha KK; Choc MG; Robinson WT
Drug Metabol Drug Interact; 1988; 6(3-4):425-37. PubMed ID: 3271648
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics and density functional studies on the metabolic selectivity of antipsychotic thioridazine by cytochrome P450 2D6: Connection with crystallographic and metabolic results.
Sasahara K; Mashima A; Yoshida T; Chuman H
Bioorg Med Chem; 2015 Sep; 23(17):5459-65. PubMed ID: 26264841
[TBL] [Abstract][Full Text] [Related]
17. A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites.
Cohen BM; Lipinski JF; Waternaux C
Psychopharmacology (Berl); 1989; 97(4):481-8. PubMed ID: 2498945
[TBL] [Abstract][Full Text] [Related]
18. Identification of lactams as in vitro metabolites of piperidine-type phenothiazine antipsychotic drugs.
Lin G; Chu KW; Damani LA; Hawes EM; Midha KK
J Pharm Biomed Anal; 1996 Apr; 14(6):727-38. PubMed ID: 8807548
[TBL] [Abstract][Full Text] [Related]
19. Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics.
Young AS; Faraone SV; Brown WA
J Clin Psychopharmacol; 1989 Oct; 9(5):361-3. PubMed ID: 2571620
[TBL] [Abstract][Full Text] [Related]
20. Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients.
Shvartsburd A; Nwokeafor V; Smith RC
Psychopharmacology (Berl); 1984; 82(1-2):55-61. PubMed ID: 6420831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
